Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent
Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial
ETP-ALL May Be Linked To Acute Myeloid Leukemia
CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup
BRCA1 and BRCA2 Mutations Linked To Higher Survival
Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease
Chromosomal Abnormalities Predict Long Median Survival
Analysis Shows No Mortality Benefit From Regular PSA Screening
Ovarian Cancer Symptom Indices May Need to be Re-Evaluated
Self-Collected Pap Smear Tests Could Advance HPV Screening
Trials Approved by NCI CTEP For the Month of January
Palmetto Establishes Coverage For Thyroid Genomic Test
FDA Approves Inlyta Pill For Renal Cell Carcinoma
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop